ALLR · XBRL financial data

Allarity Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ALLR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	1,948	2,623*	2,170	1,058	1,021	1,847*	1,403	2,321	1,203	1,674*	1,297	1,345
General and administrative	2,478	2,256*	2,070	2,313	1,589	5,470*	1,633	1,812	1,315	1,564*	1,416	1,326
Total operating expenses	4,426	4,879*	4,240	3,371	12,313	7,317*	3,036	4,133	2,518	3,238*	2,713	2,671
Operating income (loss)	(4,426)	(4,879)*	(4,240)	(3,371)	(12,313)	(7,317)*	(3,036)	(4,133)	(2,518)	(2,918)*	(2,688)	(2,671)
Interest income	12	3*	0	53	261	219*	222	237	187	155*	163	217
Interest expense	34	230*	102	426	50	75*	57	12	57	59*	229	719
Other income (expense)	(21)	—	—	—	—	—	—	—	—	—	—	—
Income tax expense (benefit)	0	83*	(4)	0	(377)	0*	0	0	0	0*	—	—
Net income (loss)	(4,447)	(1,722)*	(3,843)	(1,629)	(11,590)	(7,453)*	(2,732)	(2,320)	(2,806)	(3,373)*	(2,750)	(3,405)
Earnings per share, basic USD per share	(2.24)	—	(22.14)	(0.11)	(7.71)	—	(0.25)	(0.15)	(0.19)	(0.21)*	(0.17)	(0.21)
Earnings per share, diluted USD per share	(2.03)	—	(22.14)	(0.11)	—	—	—	—	—	—	—	—
Weighted average shares, basic thousands of shares	2,475	—	175	14,979	1,576	—	11,147	15,543	14,740	16,028*	15,969	15,911
Weighted average shares, diluted thousands of shares	2,475	—	175	14,979	—	—	—	—	—	—	—	—

Fiscal quarters (ALLR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1,399	166	312	19,233	18,500	19,533	25,201	17,801	16,895	14,687	19,812	16,982
Total current assets	4,387	1,971	2,295	21,309	20,366	22,341	29,422	20,883	20,466	17,928	34,503	31,729
Property and equipment, net	29	20	18	17	12	309	308	322	330	330	420	386
Total assets	13,875	11,862	11,969	30,883	20,378	22,650	29,730	21,205	20,796	18,258	34,923	32,115
Accounts payable	6,347	8,416	11,058	7,753	4,693	4,182	4,347	4,605	4,602	4,282	4,235	4,113
Accrued liabilities	1,485	1,309	1,553	1,465	1,322	5,232	5,275	2,977	2,712	2,667	2,191	1,971
Total current liabilities	15,744	14,167	18,008	10,616	7,414	10,839	11,061	9,038	8,785	8,430	28,003	28,579
Total liabilities	17,254	14,613	18,440	11,048	7,414	10,839	11,061	9,038	8,785	8,430	28,003	28,579
Accumulated deficit	(92,729)	(94,451)	(98,294)	(99,923)	(111,513)	(118,966)	(121,698)	(124,018)	(126,824)	(130,197)	(132,947)	(136,352)
Total stockholders' equity	(3,379)	(2,751)	(6,471)	19,835	12,964	11,811	18,669	12,167	12,011	9,828	6,920	3,536
Total liabilities and equity	13,875	11,862	11,969	30,883	20,378	22,650	29,730	21,205	20,796	18,258	34,923	32,115
Common shares outstanding (cover page) thousands of shares	4,559	6,179	17,607	42,380	4,434	17,015	15,080	14,620	15,812	15,819	15,911	15,911

Fiscal quarters (ALLR's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,447)	(1,722)*	(3,843)	(1,629)	(11,590)	(7,453)*	(2,732)	(2,320)	(2,806)	(3,373)*	(2,750)	(3,405)
Stock-based compensation	124*	(254)*	(121)	111*	17*	64*	139	164*	132*	47*	160	188*
Depreciation and amortization	—	year only	2	1*	—	year only	11	12*	—	—	—	—
Net cash from operating activities	(5,376)*	(1,672)*	(1,487)	(7,216)*	(5,443)*	(3,206)*	(2,686)	(5,481)*	(3,410)*	(3,243)*	(4,493)	(2,564)*
Purchases of property and equipment	—	year only	—	—	—	year only	0	0*	—	year only	64	0*
Net cash from investing activities	—	year only	—	—	—	year only	0	0*	—	year only	(64)	0*
Proceeds from issuing common stock	—	0*	40	27,652	5,427*	4,235*	11,143	0*	0*	0*	0	0*
Share repurchases	—	—	—	—	0*	0*	0	2,565*	141*	484*	262	0*
Net cash from financing activities	6,450*	522*	1,380	26,309*	4,868*	4,235*	11,143	(2,565)*	2,310*	(240)*	19,740	0*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Allarity Therapeutics	16,982	not reported	(2,564)*	15.9M	6.6 quarters	Q2 FY26 10-QJun 30, 2026
X4 Pharmaceuticals	185,801	2,879	(20,186)*	102.1M	9.2 quarters	Q3 FY26 10-QSep 30, 2026
Akari Therapeutics	7,694	not reported	(3,109)*	155.8B	2.5 quarters	Q2 FY26 10-QJun 30, 2026
ProPhase Labs	20	1,011	(78)*	15.6M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Pluri	3,529	335*	(4,443)*	12.3M	0.8 quarters	Q4 FY26 10-KJun 30, 2026
Edesa Biotech	10,300	not reported	(3,083)*	9.6M	3.3 quarters	Q3 FY26 10-QJun 30, 2026
CalciMedica	18,617	not reported	(4,620)*	34.1M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
GeoVax Labs	3,143	not reported	(3,658)*	7.4M	0.9 quarters	Q2 FY26 10-QJun 30, 2026
Earth Science Tech	631	9,026	707	287.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.